4:18 PM ET
10-Q
Financial Results
Genprex Q3 2026 Results: Net Loss of $4.24M, Loss Widens
Genprex, Inc. reported a net loss of $13.1 million for the nine months ended September 30, 2026, compared to $12.4 million in the prior year period. The company significantly strengthened its cash position to $15.3 million through $18.7 million in net proceeds from common stock issuances, supporting its ongoing clinical development of gene therapies for oncology and diabetes.
- Key figure
- Net loss $4.24M